Baird raised the firm’s price target on Cencora (COR) to $307 from $305 and keeps an Outperform rating on the shares. The firm noted it was ...

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments.

Over the past year, many Cencora, Inc. ( NYSE:COR ) insiders sold a significant stake in the company which may have... CONSHOHOCKEN, Pa., February 07, 2025--Cencora, Inc. (NYSE: COR) today ...

Cencora (NYSE:COR) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding ...

Reports Q1 revenue $81.5B, consensus $78.22B. “Cencora (COR) delivered an excellent start to fiscal 2025 as we focused on advancing our core ...